2BB score and signals
Viridian Therapeutics, Inc.’s current 2BB score is 33 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 12 | Very Low |
| Momentum | 50 | Stable |
| Financial strength | 65 | Strong |
| Quality | 100 | Very Strong |
| Risk | 44 | Moderate |
Company facts
| Headquarters | Waltham, Massachusetts, United States |
| Founded | 2010 |
| Employees | 252 |
| 52-week range | $13.19 – $34.29 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-24 | — | -0.9056 | — | $20.10M |
| 2026-11-03 | — | -0.925 | — | $10.87M |
| 2026-08-12 | — | -1.0499 | — | $22,756.00 |
| 2026-05-04 | — | -1.0316 | — | $17,003.00 |
2BBBullish & Bearish